Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Malignant Pleural Effusion Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) | DelveInsight

globenewswire.com
CRSP Mentioned as a key company in the malignant pleural mesothelioma market pipeline, but no specific details on their involvement or impact on the malignant pleural effusion market. MRK Mentioned as a key company in the malignant pleural mesothelioma market pipeline, but no specific details on their involvement or impact on the malignant pleural effusion market. NVS Mentioned multiple times as a key company in malignant pleural mesothelioma market reports and pipelines, but no specific details on their involvement or impact on the malignant pleural effusion market. BMY Mentioned as a key company in malignant pleural mesothelioma market reports and pipelines, but no specific details on their involvement or impact on the malignant pleural effusion market. AZN Mentioned as a key company in malignant pleural mesothelioma market reports and pipelines, but no specific details on their involvement or impact on the malignant pleural effusion market. PFE Mentioned as a key company in malignant mesothelioma market pipeline, but no specific details on their involvement or impact on the malignant pleural effusion market. REGN The article mentions 'RS Oncology' and 'RSO-021'. While RS Oncology is not a publicly traded company, Regeneron Pharmaceuticals (REGN) is a major player in the biotech sector and could potentially be involved in similar research or development, however, the article does not explicitly mention REGN.

Malignant Pleural Effusion Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) | DelveInsight New York, USA, July 20, 2026 (GLOBE NEWSWIRE) -- Malignant Pleural Effusion Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) | DelveInsight

The malignant pleural effusion market is expected to witness steady growth over the coming years, driven by the increasing incidence of metastatic cancers, particularly lung, breast, and ovarian cancers. Rising awareness, improved diagnostic techniques, and advancements in minimally invasive drainage and pleural management procedures are contributing to market expansion. Additionally, the launch of emerging therapies such as PTS500 (Gongwing Biopharm), M701 (Wuhan YZY Biopharma), RSO-021 (RS Oncology), and others will further propel the market growth.

Recently published Malignant Pleural Effusion Market Insights report includes a comprehensive understanding of current treatment practices, malignant pleural effusion emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Malignant Pleural Effusion Market Summary

Discover malignant pleural effusion market growth opportunities @ http://delveinsight.com/report-store/malignant-pleural-effusion-market

Key Factors Driving the Growth of the Malignant Pleural Effusion Market

Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that the malignant pleural effusion market growth is anticipated to rely on epidemiological studies identifying patient populations most likely to benefit from new therapies. Singh further added that understanding incidence and survival rates is key for drug development. While emerging treatments may address these gaps, their success will depend on robust clinical results and timely regulatory approvals.

Malignant Pleural Effusion Market Analysis

Learn more about disease-modifying therapies for malignant pleural effusion @ Malignant Pleural Effusion Treatment Market

Malignant Pleural Effusion Competitive Landscape

Some of the malignant pleural effusion drugs under development include PTS500 (Gongwing Biopharm), M701 (Wuhan YZY Biopharma), RSO-021 (RS Oncology), and others.

YZY Biopharma’s M701 is a first-in-class biologic for the treatment of malignant pleural effusion (MPE) and malignant ascites associated with cancer. The drug is a bispecific antibody that simultaneously targets EpCAM on tumor cells and CD3 on T cells, facilitating the interaction between immune cells and cancer cells. This dual-targeting mechanism promotes T-cell activation and enhances tumor cell destruction within the pleural or peritoneal cavity. By administering M701 through intrapleural or intraperitoneal infusion, localized immune-mediated antitumor activity can be achieved. The candidate is currently being evaluated in a Phase II clinical trial for MPE secondary to non-small cell lung cancer (NSCLC).

RS Oncology’s RSO-021 is an innovative formulation of thiostrepton being advanced for clinical development. It functions as a covalent inhibitor of PRX3, irreversibly binding to active-site cysteine residues and suppressing PRX3 peroxidase activity. This mechanism elevates oxidative stress within cancer cells beyond survivable levels, resulting in tumor cell death. RSO-021 is undergoing investigation in a Phase I/II clinical trial (NCT05278975) involving patients with MPE arising from solid tumors as well as mesothelioma. According to the clinical trial record, the study status is currently reported as unknown. The therapy is administered weekly through an indwelling intrapleural catheter and treatment continues until disease progression, unacceptable toxicity, patient withdrawal, or study discontinuation.

Gongwin Biopharm’s PTS-500 is an experimental therapy specifically designed for the management of MPE. The drug contains para-toluene-sulfonamide (PTS) as its active ingredient and is intended to selectively target and eliminate cancer cells while minimizing damage to normal tissues. Potential benefits include delayed recurrence of pleural effusions and improved patient comfort. PTS-500 is currently being assessed in Phase II clinical studies in Taiwan, and the company plans to expand development through multicenter Phase II/III trials across several countries, including the United States.

The anticipated launch of these emerging malignant pleural effusion therapies are poised to transform the malignant pleural effusion market landscape in the coming years. As these cutting-edge malignant pleural effusion therapies continue to mature and gain regulatory approval, they are expected to reshape the malignant pleural effusion market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about emerging malignant pleural effusion therapies, visit @ Malignant Pleural Effusion Medication

What is Malignant Pleural Effusion?

Malignant pleural effusion (MPE) is the abnormal accumulation of fluid in the pleural space, the cavity between the lungs and the chest wall, caused by the presence of cancer cells or cancer-related processes. It is a common complication of advanced malignancies, particularly lung cancer, breast cancer, lymphoma, and mesothelioma, and is often associated with disease progression and a poor prognosis. Patients with malignant pleural effusion typically present with symptoms such as shortness of breath, chest pain, cough, and reduced exercise tolerance, which can significantly impair quality of life. Diagnosis is usually confirmed through imaging studies and cytological examination of pleural fluid. Management focuses on symptom relief and may include thoracentesis, indwelling pleural catheters, pleurodesis, and treatment of the underlying malignancy.

Malignant Pleural Effusion Epidemiology Segmentation

The malignant pleural effusion epidemiology section provides insights into the historical and current malignant pleural effusion patient pool and forecasted trends for the leading markets. In 2025, there were approximately 50,000 incident cases of MPE due to breast cancer and more than 25,000 cases due to lymphoma across EU4 and the UK.

The malignant pleural effusion market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand the future of malignant pleural effusion treatment @ Malignant Pleural Effusion Treatment Options

Scope of the Malignant Pleural Effusion Market Report

Discover more about next-generation malignant pleural effusion drugs @ Malignant Pleural Effusion Clinical Trials

Table of Contents

Related Reports

Malignant Pleural Effusion Clinical Trial Analysis

Malignant Pleural Effusion Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant pleural effusion companies, including LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group, and others.

Malignant Pleural Mesothelioma Market

Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key malignant pleural mesothelioma companies including AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, Sellas Life Sciences Group, CRISPR Therapeutics AG, Vivace Therapeutics, NuCana plc, A2 Biotherapeutics, Tango Therapeutics, and others.

Malignant Pleural Mesothelioma Clinical Trial Analysis

Malignant Pleural Mesothelioma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant pleural mesothelioma companies, including MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc., Novartis, Bristol-Myers Squibb, Novartis, TCR2 Therapeutics, Novotech (Australia) Pty Limited, AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.

Malignant Mesothelioma Market

Malignant Mesothelioma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key malignant mesothelioma companies including Bristol Myers Squibb, PrECOG, Astrazeneca, and others.

Malignant Mesothelioma Clinical Trial Analysis

Malignant Mesothelioma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant mesothelioma companies, including Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.